SCHEDULE: Vestal Point Capital Discloses 9.95% Stake in Dianthus
Beneficial Ownership Report
Vestal Point Capital, LP and Ryan Wilder have disclosed a 9.95% beneficial ownership stake in Dianthus Therapeutics, Inc., holding 3.2 million shares of common stock.
Summary
- Vestal Point Capital, LP and Ryan Wilder reported beneficial ownership of 3,200,000 shares of Dianthus Therapeutics, Inc. common stock.
- This represents 9.95% of the company's outstanding common stock.
- The percentage is calculated based on 32,159,982 shares outstanding as of May 7, 2025, as reported in the company's Quarterly Report on Form 10-Q.
- The shares are held by the Vestal Point Fund and Account, for which Vestal Point Capital, LP acts as investment adviser and Ryan Wilder is the Chief Investment Officer and Managing Partner.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a change or update to a previously reported beneficial ownership.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership by an investment firm and does not contain performance data, forward-looking statements, or strategic updates from the issuer. The disclosure of a significant stake by an institutional investor is generally viewed as a neutral to slightly positive signal of confidence.
Positives
- A significant beneficial ownership stake by Vestal Point Capital, LP, an investment firm, may signal confidence in Dianthus Therapeutics, Inc.
Related Party Transactions
- Vestal Point Master Fund, LP, a fund managed by Vestal Point Capital, LP, has the right to receive or direct the receipt of dividends or proceeds from the sale of more than 5% of Dianthus Therapeutics, Inc. common stock.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may influence investor perception and potentially stock price, signaling institutional confidence.
- Company Management: Awareness of a significant institutional shareholder may influence strategic decisions or engagement with the investor.
Key Dates
| Date | Description |
|---|---|
| 05/07/2025 | Date as of which 32,159,982 shares of Common Stock were outstanding, as reported in the Company's Form 10-Q. |
| 05/12/2025 | Date Dianthus Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025. |
| 06/30/2025 | Date of event which requires filing of this statement. |
| 08/14/2025 | Date the Schedule 13G was signed and filed. |
Keywords
Dianthus Therapeutics, Vestal Point Capital, Ryan Wilder, Schedule 13G, beneficial ownership, common stock, institutional investment, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.